Hindryckx, Pieter
Jairath, Vipul
D'Haens, Geert
Article History
First Online: 1 September 2016
Competing interests
: P.H. has received consulting fees from Abbvie and Takeda and speakers fees from AbbVie, Chiesi, Ferring, Falk Pharma, Tillotts Pharma and Vifor Pharma. V.J. has received scientific advisory board fees from AbbVie and Sandoz and speakers fees from Janssen and Takeda. G.D. has received consulting fees from AbbVie, ActoGeniX NV, Amgen, AM-Pharma BV, Boehringer-Ingelheim, Centocor/Janssen Biologics, ChemoCentryx, Cosmo Technologies, Elan/Biogen, EnGene, Ferring Pharmaceuticals, Gilead Sciences, Given Imaging, GlaxoSmithKline, Merck Research Laboratories, Merck Serono, Millenium Pharmaceuticals, Novo Nordisk, NPS Pharmaceuticals, PDL Biopharma, Pfizer, Receptos, Salix Pharmaceuticals, Schering Plough, Shire Pharmaceuticals, Sigmoid Pharma, Teva Pharmaceuticals, Tillotts Pharma and UCB Pharma; research grants from AbbVie, Falk, Given Imaging; GlaxoSmithKline, Janssen and Merck; and lecture/speakers bureaux fees from AbbVie, Jansen, Merck, Shire, Takeda and UCB.